 1. Have histologically confirmed adenocarcinoma of the prostate, with clinically significant bone metastases exhibiting castrate-resistant progression. Progression is defined as any of the following: 1 New lesions or obviously worsening lesions on bone scan within the previous three months; 2 a PSA doubling time of 3 months; 3 New or progressive symptoms requiring a change in therapy that are referable to the cancer; 4 New extra-osseous lesions within the past 3 months 